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PURPOSE: To identify the dose-response relationship between visits to a chiropractor for spinal
manipulation and chronic low back pain (cLBP) outcomes and to determine the efficacy of manip-
ulation by comparison with a light massage control.
STUDY DESIGN/SETTING: Practice-based randomized controlled trial.
PATIENT SAMPLE: Four hundred participants with cLBP.
OUTCOME MEASURES: The primary cLBP outcomes were the 100-point modified Von Korff
pain intensity and functional disability scales evaluated at the 12- and 24-week primary end points.
Secondary outcomes included days with pain and functional disability, pain unpleasantness, global
perceived improvement, medication use, and general health status.
METHODS: One hundred participants with cLBP were randomized to each of four dose levels of
care: 0, 6, 12, or 18 sessions of spinal manipulation from a chiropractor. Participants were treated
three times per week for 6 weeks. At sessions when manipulation was not assigned, they received
a focused light massage control. Covariate-adjusted linear dose effects and comparisons with the
no-manipulation control group were evaluated at 6, 12, 18, 24, 39, and 52 weeks.
RESULTS: For the primary outcomes, mean pain and disability improvement in the manipulation
groups were 20 points by 12 weeks and sustainable to 52 weeks. Linear dose-response effects were
small, reaching about two points per six manipulation sessions at 12 and 52 weeks for both vari-
ables (p!.025). At 12 weeks, the greatest differences from the no-manipulation control were found
for 12 sessions (8.6 pain and 7.6 disability points, p!.025); at 24 weeks, differences were negligi-
ble; and at 52 weeks, the greatest group differences were seen for 18 visits (5.9 pain and 8.8 dis-
ability points, p!.025).
CONCLUSIONS: The number of spinal manipulation visits had modest effects on cLBP out-
comes above those of 18 hands-on visits to a chiropractor. Overall, 12 visits yielded the most favor-
able results but was not well distinguished from other dose levels.
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Context
The impact of spinal manipulation on chronic low back
pain compared to light massage, serving as a control, is
assessed by the authors.
Contribution
In this well-performed RCT, spinal manipulation for 18
visits was found to result in modestly improved out-
comes relative to light massage, but such improvements
may not be clinically significant. They also found that
the best treatment effects for manipulation were at 12
sessions versus the control and no additional benefit
was afforded at 18 sessions.
Implications
This study provides some guidance where there is cur-
rently little. Twelve chiropractic sessions are reasonable,
manipulation may be modestly better than light massage
at this endpoint, but not at 24 weeks. As important, the
study serves as a reasonable model for the design of
a practice-based randomized trial.
—The Editors
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It has long been known that low back pain (LBP) is
a prevalent and costly condition [1,2] and that chiropractors
provide the vast majority of spinal manipulation [3] and
treat a large proportion of LBP in the United States [4].
It is therefore important to determine the optimal quantity
of spinal manipulative therapy (SMT), particularly for
chronic low back pain (cLBP) [5].
Recommendations for duration and frequency of SMT/
chiropractic care for cLBP have varied widely and have long
been based on the clinical experience and opinion [6]. In the
early 1990s, a multidisciplinary RAND panel found that
opinion was too varied to come to a formal evidence-based
consensus (2–24 weeks of care, 1–5 visits per week), but
on average, members expected the typical patient to improve
in 4 to 6 weeks with three visits per week [7]. In contrast, an
all-chiropractic RAND expert panel recommended 30 visits
over 14 weeks [8]. Shekelle et al. [3] noted a range of 1 to 19
visits in the published studies of chiropractic care. Later,
Nyiendo et al. [9] found a mean of 6.7 visits (standard devi-
ation [SD]57.5, range51–56) in a practice-based cohort of
526 nonspecific cLBP patients.
To this day, there is no consensus on the efficacy of SMT
and its role in the care of cLBP. Some systematic reviews
have reported quality evidence in support of SMT [10,11],
whereas others including the latest Cochrane review found
SMT to be no better than other interventions [12]. Results
of systematic reviews, whether meta-analysis or best-
evidence synthesis, may depend on the quantity of care used
in the trials included in the reviews. Investigators have had
virtually no evidence from dose-response trials to inform
the number of SMT sessions provided.
Because of the dearth of evidence for duration and fre-
quency of care, we conducted the first pilot randomized
trial evaluating dose-response of SMT (n572) [5]. We
found a clinically important association between number
of visits to a chiropractor (1–4 weekly visits for 3 weeks)
and short-term pain and disability relief showing that
a higher number of visits yielded more favorable results.
We have subsequently conducted the current 5-year study,
the first full-scale dose-response trial with the aim of iden-
tifying optimal care of cLBP with SMT and informing the
design of comparative effectiveness studies. We also evalu-
ated the efficacy of the SMT dose levels by testing the hy-
pothesis of no difference between SMT and a hands-on
control. The trial evaluated the unique contribution of
SMT to outcomes beyond the effects of a light massage
to control attention (quantity of visits) and touching the pa-
tient, history, and context [13].
Methods
Design
In a prospective open-label randomized controlled trial,
400 participants with nonspecific cLBP were randomized toreceive a dose of 0, 6, 12, or 18 SMT sessions from a chiro-
practor. All participants were assigned 18 treatment visits,
3 per week for 6 weeks. Spinal manipulative therapy was
performed at the assigned number of visits, and a brief light
massage control was performed at non-SMT visits to con-
trol provider attention and touching the participants [14].
For example, those receiving 12 visits for SMT received
6 visits for light massage from the chiropractor (Fig. 1).
Follow-up evaluation was by mailed questionnaire or
blinded phone interview at 6, 12, 18, 24, 39, and 52 weeks
after randomization. The primary outcomes were prespeci-
fied as self-reported pain intensity and functional disability
at the 12- and 24-week end points. The primary end points
were chosen to emphasize a short- and a long-term post-
treatment time point.
Randomization was conducted using computer-generated
design-adaptive allocation [15,16] to balance six baseline
variables across groups: pain and disability scores, age, gen-
der, relative confidence in SMTand massage, and any previ-
ous SMT or massage care. Allocation to study groups was
hence concealed from all study personnel and participants
by requiring entry of data into the computer program col-
lected immediately before randomization (pain, disability,
and confidence in treatment success). Patient coordinators
called in the allocation variables over the phone to research
staff who entered the data into the allocation computer pro-
gram. The patient coordinator then assigned the participant
to group by placing an unmarked sealed envelope identify-
ing care in the patient’s clinic file. Participants and treating
visits attended
(nonadherent < 75%)
1 – 4:  n =     4
5 – 8:  n =     0
9 – 13: n =     3
14 – 17: n = 0
18: n=   93
Treatment non-
compliance
Medical =    0
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Unknown =    1
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1 – 4:  n =     3
5 – 8:  n =   1
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18: n=   90
Treatment non-
compliance
Medical =     0
Personal =     8
Unknown =    1
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(nonadherent < 75%)
1 – 4:  n =     3
5 – 8:  n =     2
9 – 13: n =     2
14 – 17: n = 0
18: n=   93
Treatment non-
compliance
Medical =     2
Personal =     5
Unknown =     0
visits attended
(nonadherent < 75%)
1 – 4:  n =     2
5 – 8:  n =     2
9 – 13: n =     0
14 – 17: n = 1
18: n=   95 
Treatment non-
compliance
Medical =    0
Personal =    4
Unknown =    0
Not eligible = 3
Not interested = 0
Not eligible = 101
Not interested = 11
Baseline Exam 1 (n = 522)
Not eligible = 2306
Not interested = 382
No show = 6
Baseline Exam 2 (n = 403)
Phone Screen (n = 3353)
Cancelled = 72
No show = 71
follow-up 
6 wk: n = 95
12 wk: n = 85
18 wk: n = 86
24 wk: n = 82
39 wk: n = 84
52 wk: n = 81
Lost to follow-up
Address = 1
Medical = 0
Personal = 3
Unknown = 1
follow-up 
6 wk: n = 97
12 wk: n = 90
18 wk: n = 94
24 wk: n = 86
39 wk: n = 83
52 wk: n = 86
Lost to follow-up
Address = 0
Medical = 0
Personal = 1
Unknown = 0
follow-up 
6 wk: n = 96
12 wk: n = 89
18 wk: n = 94
24 wk: n = 89
39 wk: n = 87
52 wk: n = 85
Lost to follow-up
Address = 0
Medical = 2
Personal = 1
Unknown = 0
follow-up 
6 wk: n = 99
12 wk: n = 92
18 wk: n = 96
24 wk: n = 93
39 wk: n = 87
52 wk: n = 88
Lost to follow-up
Address = 0
Medical = 0
Personal = 0
Unknown = 0
0 SMT + 18 LM 
(n = 100)
6 SMT + 12 LM
(n = 100)
12 SMT + 6 LM
(n = 100)
18 SMT + 0 LM
(n = 100)
Randomization (n = 400)
Included in analysis
n = 95
Reason for exclusion:
No follow-up data
Non-compliant n = 4
Compliant n = 1
Included in analysis
n = 99
Reason for exclusion:
No follow-up data
Non-compliant n = 1
Included in analysis
n = 97
Reason for exclusion:
No follow-up data
Non-compliant n = 3
Included in analysis
n = 100
Reason for exclusion:
NA
Fig. 1. Study flow diagram. All participants were assigned 18 treatment visits. They received either spinal manipulative therapy (SMT) or light massage
control (LM) at any one visit.
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tion. However, patient coordinators, who collected some
outcomes by phone interview, remained blinded to group as-
signment throughout the study.The study was approved by
the University of Western States Institutional Review Board
(FWA 851). The trial was registered at ClinicalTrials.gov,
NCT00376350.
Protocol overview
Participants were recruited through craigslist, mailers,
and local newspapers. They were informed that the study
was investigating 18 visits for different combinations of
two manual therapies for cLBP. Preliminary screening
was conducted through telephone interview by study staff.
At the first baseline visit, participants signed an informed
consent form and filled out a baseline survey. Eligibility
screening examinations were then conducted at a central
university clinic by one of the two licensed chiropractors
(faculty withO20 years of experience) using history, phys-
ical examination, and lumbar X-rays [17].
Eligible participants selected a convenient clinic for
study care. Care was provided by one of the 12 licensed chi-
ropractors with 4 to 24 years of experience in 9 Portland-area
clinics. The treating chiropractors were selected because
their abilities were known to the authors, and some had
previous experience on our trials. After a second baseline
survey at the clinic, participants were given a brief confirma-
tory screening examination by the treating clinician. They
were then randomized and received their first treatment. Par-
ticipants were compensated for each treatment visit, mailed
questionnaires, and phone interviews ($10–$20). Partici-
pants signed an informed consent form.
Participants
Participants were required to be at least 18 years old and
have a current episode of cLBP [18] of mechanical origin
[19] of at least 3 months duration [3]. They were further re-
quired to have had some LBP on 30 days in the previous 6
weeks and a minimum LBP index of 25 on a 100-point
scale to prevent floor effects. Participants were excluded
if they received manual therapy within the previous 90 days
or for contraindications to study interventions [17,20] and
complicating conditions such as active cancer, spine pathol-
ogy, inflammatory arthropathies, autoimmune disorders,
anticoagulant conditions, neurodegenerative diseases, pain
radiating below the knee, organic referred pain, pregnancy,
and disability compensation.
Intervention
Each visit was 15 minutes long with a treating chiro-
practor, consistent with chiropractic practice [21]. Partici-
pants received a hot pack for 5 minutes to relax spinal
muscles followed by 5 minutes for the SMT or control in-
tervention. The visit was completed with 5 minutes of verylow-dose pulsed ultrasound (20% duty cycle with 0.5 watts/
cm2). This was used as a quasi-sham to enhance treatment
credibility and adherence to care [13].
Spinal manipulative therapy consisted of manual thrust
(high velocity, low amplitude) spinal manipulation in the
lumbar and transition thoracic regions, predominantly in
the side-posture position [22]. Specific manipulations to be
performed were determined at each visit by the chiropractor
through ongoing evaluation of the participants including pa-
tient progress, self-reported and provocative pain, spinal
range of motion, and palpation of the spine and paraspinal
soft tissue [17,22].Manipulationwas not performed at a visit,
if the treating chiropractor failed to find any indication.
Lighter thrust manipulation including the use of mechanical
assistance of a spring-loaded table and segmental low-
velocity mobilization were permitted in the case of acute
exacerbation of the lumbar spine pain [22].
The light massage control consisted of 5 minutes of gen-
tle effleurage and petrissage of the low back (lumbar and
lower thoracic) paraspinal muscles [22,23], focused on
the symptomatic areas. The massage used was gentler
and of shorter duration than recommended for therapeutic
massage practice [21,24]. As such, it was a minimalist
intervention to control touching the patient; it was not
a formal sham. The treating chiropractors were also asked
to render SMT and control intervention with equal enthusi-
asm to help balance expectations of treatment success im-
parted by the practitioner. Protocol standardization and
provider equipoise across treatment groups were main-
tained through quarterly training and monitored by office
observation and patient phone interview [14,25].Outcome and baseline variables
This report emphasizes the prespecified primary out-
comes, the self-reported modified Von Korff pain and dis-
ability scales validated by Underwood et al. [26]. The
pain score is the average of three 11-point numeric rating
scales converted to a 100-point scale: back pain today,
worst back pain in the last 4 weeks, and average back pain
in the last 4 weeks. The disability score is also the average
of three scales: interference with daily activities, social and
recreational activities, and the ability to work (outside or
around the house).
Secondary outcomes included pain unpleasantness [27],
Physical and Mental Component Summary Scales of the
short-form 12 [28], Health State Visual Analog Scale
from EuroQol [29], perceived pain and disability improve-
ment, and the number of the following in the previous 4
weeks: days with pain and disability and medication use.
Additional baseline variables included demographics,
Fear-Avoidance Beliefs Questionnaire [30], confidence in
treatment success [14], and any from a list of comorbid
conditions (arthritis, asthma or allergies, gastrointestinal
problems, gynecological problems, hypertension, or other
chronic condition) [31].
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An intention-to-treat analysis was conducted with each
participant included in the original allocation group; miss-
ing data were imputed using linear interpolation and then
last datum was carried forward. Nine participants were
omitted from the analysis because they had no follow-up
data. A sensitivity analysis with all missing data excluded
was conducted for the two primary outcomes.
The prespecified primary analysis consisted of regre-
ssion models to identify the linear effect of SMT dose
(slope5outcome increment/six SMT sessions) and to com-
pare each SMT group to the no-SMT control group (adjusted
mean differences). Seemingly unrelated (simultaneous) re-
gression by Zellner [32] was used to model outcomes
for the individual time points [33]. In addition, for the pri-
mary outcomes only, longitudinal effects across all follow-
ups were modeled with generalized estimating equations
using unstructured correlation to account for within-person
correlation between time points [33]. Slopes and groupTable 1
Baseline characteristics
Sociodemographic information
SMT 0
(n595)
SM
(n5
Age (y) 40.9 (14.1) 41.
Female (%) 49 49
Non-white or Hispanic (%) 14 18
Married (%) 37 28
College degree (%) 58 63
Income!$20,000/y (%) 31 27
Smoker (%) 17 13
Expectations
Confidence in treatment success
Spinal manipulation (1–6 scale)* 3.6 (1.2) 3.
Light massage (1–6 scale)* 3.4 (1.2) 3.
Previous treatment
Spinal manipulation (%) 71 70
Light massage (%) 52 56
LBP complaint
Pain intensity (0–100 scale)y 52.2 (16.3) 51.
Functional disability (0–100 scale)y 45.2 (21.8) 44.
Pain unpleasantness (0–100 scale)y 41.7 (19.5) 41.
Days with pain (last 4 wk) 24.8 (4.8) 24.
Days with disability (last 4 wk) 7.4 (8.1) 6.
Duration (y) 11.6 (9.5) 11.
Health status
SF-12 physical health componentz 43.0 (9.5) 43.
SF-12 mental health componentz 50.2 (10.5) 48.
Health state (0–100 Visual Analog Scale)z 70.1 (17.2) 72.
Other comorbidity (%) 58 57
Fear-Avoidance Beliefs Questionnaire
Work beliefs (0–100 scale)z 36.6 (23.2) 32.
Activity beliefs (0–100 scale)z 55.0 (20.1) 53.
Oral medication use (times in last 4 wk)
Prescription 0.9 (3.6) 0.
Nonprescription 7.6 (10.0) 8.
SMT, spinal manipulation; SF-12, short-form 12; LBP, low back pain.
Values are mean (standard deviation) or percentage.
* Six-point Likert scale with 1 indicating lowest and 6 indicating highest co
y Lower scores favorable. Low back pain intensity and functional disability
z Higher scores favorable. Short-form 12 health survey scores are standardizcomparisons were adjusted for the six baseline balancing
variables used to randomize the participants [15,16]: pain
and disability scores, age, gender, relative confidence in
SMT and massage, and any previous SMT or massage care.
The baseline value of the outcome measure was added as
a covariate if not already included among the six balancing
variables.
In a prespecified secondary ‘‘responder’’ analysis, the
two primary outcomes were dichotomized to show the
proportion of participants with 50% improvement. The
analysis mentioned previously was then repeated using
binomial regression to identify slopes and group differences
in proportion of responders [33].
The sample size was determined a priori to have at least
80% power to detect a between-group effect of 10 of
100 points in the two primary outcomes using a two-
tailed test. It took into consideration a 10% dropout rate.
The .025 level of significance was used to adjust for having
two primary outcomes. Detection of a 10-point between-T 6
99)
SMT 12
(n597)
SMT 18
(n5100)
All
(n5391)
4 (14.8) 41.8 (14.0) 41.2 (13.8) 41.3 (14.1)
49 52 50
11 16 15
41 36 36
51 53 56
19 28 26
6 8 11
8 (1.1) 3.7 (1.2) 3.8 (1.1) 3.7 (1.2)
5 (1.2) 3.4 (1.2) 3.5 (1.2) 3.5 (1.2)
74 72 72
43 54 51
0 (18.2) 51.6 (17.5) 51.5 (16.8) 51.6 (17.2)
8 (24.0) 46.1 (23.4) 45.2 (21.8) 45.3 (22.7)
1 (21.1) 40.3 (22.8) 42.4 (22.2) 41.4 (21.4)
1 (5.5) 23.3 (5.7) 24.1 (4.6) 24.1 (5.2)
7 (7.5) 6.8 (7.5) 6.5 (7.2) 6.8 (7.6)
2 (9.8) 11.7 (10.4) 12.5 (9.5) 11.8 (9.8)
8 (8.9) 44.3 (8.4) 42.3 (8.8) 43.3 (8.9)
6 (10.5) 47.6 (11.2) 49.4 (9.6) 48.9 (10.5)
1 (13.8) 73.5 (14.4) 68.2 (17.4) 70.9 (15.8)
52 54 55
0 (23.4) 31.0 (18.9) 32.2 (21.4) 32.9 (21.8)
8 (23.1) 56.4 (17.7) 58.8 (19.8) 56.0 (20.3)
3 (1.1) 0.6 (2.6) 0.3 (1.5) 0.5 (2.4)
9 (10.8) 9.5 (10.0) 7.6 (9.4) 8.4 (10.1)
nfidence.
evaluated with modified Von Korff scales.
ed to the US general population (mean550, standard deviation510).
Table 2
Primary outcomes
Time
Observed unadjusted mean (SD) Slope (95% CI) Adjusted mean difference (95% CI)
SMT 0 SMT 6 SMT 12 SMT 18 Per six SMT sessions SMT 0 vs. 6 SMT 0 vs. 12 SMT 0 vs. 18
Pain intensity (0–100 scale)
0 wk 52.2 (16.3) 51.0 (18.2) 51.6 (17.5) 51.5 (16.8) — — — —
6 wk 34.5 (18.4) 32.3 (15.8) 27.1 (14.7) 30.2 (19.0) 1.8 (0.3, 3.2)* 1.7 (2.6, 5.9) 7.2 (2.8, 11.6)* 4.1 (0.5, 8.6)
12 wk 37.9 (20.4) 32.7 (19.4) 29.0 (20.8) 31.4 (19.8) 2.2 (0.6, 3.8)* 4.5 (0.6, 9.6) 8.6 (3.2, 14.0)* 6.1 (1.0, 11.2)*
18 wk 35.7 (19.5) 31.4 (18.4) 30.3 (19.3) 29.3 (19.7) 2.0 (0.4, 3.5)* 3.6 (1.3, 8.5) 5.1 (0.2, 10.0) 6.1 (1.2, 11.0)*
24 wk 34.9 (20.6) 32.5 (19.8) 33.7 (20.5) 32.1 (20.5) 0.6 (1.0, 2.3) 1.7 (3.4, 6.9) 0.8 (4.4, 6.0) 2.4 (2.9, 7.6)
39 wk 36.2 (21.0) 32.8 (21.5) 30.2 (21.7) 31.6 (21.5) 1.6 (0.2, 3.3) 2.8 (2.8, 8.4) 5.8 (0.5, 11.2) 4.3 (1.2, 9.9)
52 wk 36.5 (21.8) 30.7 (22.4) 31.9 (22.5) 28.7 (20.5) 2.2 (0.4, 4.0)* 5.4 (0.4, 11.1) 4.6 (1.2, 10.3) 7.6 (2.0, 13.2)*
6–52 wky — — — — 1.7 (0.4, 3.0)* 3.1 (1.0, 7.1) 5.3 (1.2, 9.3)* 5.0 (0.8, 9.2)*
Functional disability (0–100 scale)
0 wk 45.2 (21.8) 44.8 (24.0) 46.1 (23.4) 45.2 (21.8) — — — —
6 wk 27.0 (20.2) 28.5 (20.3) 25.8 (19.3) 30.1 (20.9) 0.6 (2.3, 1.0) 1.7 (6.8, 3.4) 1.5 (3.7, 6.6) 3.1 (8.3, 2.1)
12 wk 29.2 (23.7) 24.8 (18.6) 22.0 (20.7) 23.4 (20.5) 2.0 (0.3, 3.8)* 4.2 (1.0, 9.4) 7.5 (1.7, 13.3)* 5.8 (0.2, 11.3)
18 wk 26.1 (21.4) 23.5 (19.4) 22.1 (21.5) 22.4 (19.2) 1.3 (0.4, 2.9) 2.2 (2.8, 7.2) 4.1 (1.5, 9.7) 3.6 (1.5, 8.7)
24 wk 27.1 (25.2) 25.6 (21.7) 24.0 (20.4) 24.1 (20.3) 1.1 (0.7, 2.9) 1.4 (4.5, 7.2) 3.4 (2.4, 9.3) 2.9 (2.9, 8.8)
39 wk 26.2 (22.8) 24.5 (22.6) 21.7 (20.5) 24.1 (22.7) 0.9 (0.9, 2.8) 1.4 (4.3, 7.1) 4.7 (0.7, 10.2) 2.0 (3.9, 7.9)
52 wk 28.0 (23.7) 22.6 (22.4) 22.4 (21.2) 19.1 (18.7) 2.7 (1.0, 4.4)* 5.2 (0.5, 10.9) 5.9 (0.1, 11.8) 8.8 (3.3, 14.4)*
6–52 wky — — — — 0.9 (0.3, 2.2) 1.5 (2.1, 5.1) 3.9 (0.0, 7.7) 2.4 (1.5, 6.3)
SMT, spinal manipulative therapy; SD, standard deviation; CI, confidence interval.
Primary end points were prespecified as pain intensity and functional disability at 12 and 24 weeks. Unadjusted group means are from original data with-
out imputation; slopes and group differences are computed from imputed data adjusted for the baseline covariates. Positive signs of slopes and mean dif-
ferences were computed to favor higher doses of manipulation. A two-tailed test of statistical significance was prespecified at the .025 to account for
two primary outcomes and used for all statistical tests.
* p!.025.
y Longitudinal profile using generalized estimating equations.
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studies [31,34]. All analyses were conducted with Stata
11.2 (StataCorp, College Station, TX, USA).
Results
Participants were enrolled from March 2007 to May
2010 and followed for 1 year with the last follow-up ending
May 2011. Allocation was equally spread out across clinics
and providers with group assignments averaging 25%Fig. 2. Pain time profile. Pain intensity was evaluated on a 0 to 100 scale.
The graphs show pain development for each group at baseline and the six
follow-up time points. The primary end points were 12 and 24 weeks.
SMT, spinal manipulative therapy.(SD56%) per group per clinic and 25% (SD512%) per
group per treating physician.
The study flowchart in Fig. 1 shows strong adherence to
care with 90% to 95% of participants attending all 18 study
visits. Four participants, allocated to 18 SMT sessions and
who attended all 18 visits, collectively had 5 treatment
visits where SMT was deemed inappropriate and withheld
per protocol. Three had SMT withheld at one visit becauseFig. 3. Pain dose-response curves. The dose-response plots demonstrate
small gradients in pain intensity (0- to 100-point scale) across dose groups
for four time points: end of care (6 weeks), primary end points (12 and 24
weeks), and the final follow-up (52 weeks). Note that a line illustrates dif-
ferences across the dose groups at a particular time point, rather than
change over time for a particular dose. SMT, spinal manipulative therapy.
Fig. 4. Responders: percentage of individuals attaining 50% pain im-
provement. SMT, spinal manipulative therapy.
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visit because of acute exacerbation. There was one viola-
tion of protocol where a patient accidentally received 13
SMT visits instead of 12. Compliance with data collection
was greater than 80% for all follow-up time points. Nine
participants were completely lost to follow-up.
Medication use and care from a nonstudy provider for
cLBP were balanced across groups at each time point. Dur-
ing the treatment phase, 93% to 97% of participants in each
treatment arm refrained from professional care outside the
study and 94% to 95% abstained from prescription medica-
tion. Thereafter, approximately three-fourths reported no
outside professional care at each follow-up; the maximum
difference between groups ranged from 4% to 11% of par-
ticipants. Also, 90% refrained from prescription medication
at each follow-up with maximum group differences ranging
from 1% to 8%. Nonprescription analgesics were balanced
across groups. Confidence in the success of the twoTable 3
Responders ($50% individual improvement)
Time
Observed unadjusted % of responders Slope (95% CI)
SMT 0 SMT 6 SMT 12 SMT 18 Per six SMT ses
Pain intensity
6 wk 32.6 28.3 46.4 45.0 5.5 (1.3, 9.8)*
12 wk 28.4 38.4 49.5 37.0 3.8 (0.5, 8.1
18 wk 32.6 37.4 43.3 47.0 4.8 (0.5, 9.2)
24 wk 36.8 40.4 40.2 42.0 1.4 (2.9, 5.7
39 wk 32.6 41.4 45.4 47.0 4.8 (0.5, 9.1)
52 wk 37.9 47.5 41.2 48.0 2.5 (1.9, 6.9
Functional disability
6 wk 49.5 47.5 50.5 42.0 0.1 (0.5, 0.3
12 wk 43.2 49.5 59.8 55.0 4.4 (0.0, 8.8)
18 wk 50.5 54.5 63.9 56.0 2.5 (1.9, 6.9
24 wk 49.5 51.5 59.8 54.0 2.2 (2.2, 6.6
39 wk 51.6 56.6 61.9 54.0 1.2 (3.2, 5.6
52 wk 58.9 57.6 57.7 62.0 0.8 (3.5, 5.2
SMT, spinal manipulative therapy; CI, confidence interval.
Unadjusted group percentages are from original data without imputation; slo
adjusted for the baseline covariates. Positive signs of slopes and mean differenc
* p!.025.interventions was approximately equal and balanced across
groups.
Baseline characteristics (Table 1) were balanced across
groups with the exception of smoking; inclusion of smok-
ing in the analysis produced no substantive changes in ef-
fect sizes. The mean age was 41.3 years, and most
participants were white non-Hispanic. Half of the partici-
pants reported the following characteristics: female, college
degree, comorbidity, and experience with a study interven-
tion. The mean duration of LBP was 11.8 years. The aver-
age participant experienced LBP 6 days per week and took
medication for it twice per week.
Pain
Pain improved by the end of treatment and was durable
up to 52 weeks after randomization for all groups (Table 2
and Fig. 2). Mean pain reduction within groups reached
more than 20 points for SMT treatment arms.
Adjusted slopes and mean differences (AMD) with con-
fidence intervals are presented in Table 2 for the primary
analysis. A small statistically significant linear dose-
response effect in pain intensity across the treatment levels
was observed at the 12-week primary end point (2.2 points
per six visits, p5.007) but not at the 24-week primary end
point (0.6 points per six visits). Slopes were small at the
other time points (1.6–2.0). Overall, there were minimal
differences between adjacent dose groups at all time points
(Fig. 3).
At 12 weeks, the maximum pain difference between
treatment and no-SMT control was observed for 12 SMT
visits (AMD58.6, p5.002); at 24 weeks, there were no
meaningful differences from the control (AMD !2.5).
For the secondary time points, a notable effect was ob-
served at 52 weeks; here, 18 SMT visits showed the great-
est advantage over the control (AMD57.6, p5.011).Adjusted difference in percentage of responders (95% CI)
sions SMT 0 vs. 6 SMT 0 vs. 12 SMT 0 vs. 18
3.7 (16.2, 8.8) 13.7 (0.6, 26.9) 13.0 (0.4, 26.5)
) 10.0 (3.2, 23.1) 21.1 (7.7, 34.6)* 8.9 (4.2, 21.9)
4.3 (9.1, 17.6) 10.3 (3.3, 23.9) 14.2 (0.5, 27.9)
) 3.7 (10.0, 17.4) 3.2 (10.5, 16.9) 4.9 (8.7, 18.4)
9.0 (4.5, 22.5) 13.0 (0.7, 26.6) 14.6 (1.1, 28.1)
) 10.2 (3.5, 23.9) 3.9 (9.8, 17.6) 10.6 (3.2, 24.4)
) 2.0 (16.1, 12.0) 0.9 (13.2, 15.1) 7.5 (21.4, 6.5)
6.2 (7.7, 20.0) 16.8 (2.9, 30.6)* 11.5 (2.4, 25.4)
) 3.7 (10.4, 17.9) 13.5 (0.3, 27.2) 3.5 (8.8, 19.3)
) 2.5 (11.5, 16.5) 10.4 (3.4, 24.3) 4.8 (9.1, 18.6)
) 4.9 (9.0, 18.8) 10.4 (3.4, 24.2) 2.5 (11.5, 16.4)
) 1.1 (14.8, 12.6) 1.4 (15.4, 12.6) 2.7 (11.0, 16.5)
pes and group differences in responders are computed from imputed data
es were computed to favor higher doses of SMT.
Table 4
Secondary outcomes
Time
Observed unadjusted mean (SD) Slope (95% CI) Adjusted mean difference (95% CI)
SMT 0 SMT 6 SMT 12 SMT 18 Per six SMT sessions SMT 0 vs. 6 SMT 0 vs. 12 SMT 0 vs. 18
Pain unpleasantness (0–100 scale)
0 wk 41.7 (19.5) 41.1 (21.1) 40.3 (22.8) 42.4 (22.2) — — — —
6 wk 24.7 (21.7) 20.3 (17.5) 15.6 (17.3) 18.4 (18.1) 2.4 (0.9, 4.0)* 4.2 (0.8, 9.1) 8.7 (3.5, 14.0)* 6.6 (1.7, 11.6)*
12 wk 29.7 (22.3) 24.5 (20.6) 22.2 (22.3) 23.9 (21.3) 2.0 (0.2, 3.7) 4.8 (1.0, 10.5) 7.1 (1.1, 13.0)* 5.8 (0.1, 11.5)
18 wk 26.8 (22.3) 21.9 (21.2) 20.4 (20.4) 21.3 (21.8) 1.8 (0.1, 3.6) 4.6 (1.0, 10.3) 5.8 (0.4, 11.2) 5.8 (0.4, 11.2)
24 wk 27.4 (21.7) 24.8 (21.8) 25.0 (21.9) 24.8 (22.4) 0.7 (1.1, 2.5) 2.1 (3.5, 7.8) 2.0 (3.6, 7.5) 2.5 (3.2, 8.3)
39 wk 28.3 (21.6) 25.5 (21.3) 23.2 (20.8) 23.0 (21.1) 1.8 (0.1, 3.6) 2.4 (3.3, 8.2) 4.8 (0.6, 10.3) 5.4 (0.2, 10.9)
52 wk 27.8 (22.1) 22.1 (21.7) 24.0 (24.0) 21.5 (19.9) 1.7 (0.1, 3.5) 5.4 (0.3, 11.2) 3.7 (2.4, 9.7) 6.4 (0.7, 12.1)
Days with pain (last 4 wk)
0 wk 24.8 (4.8) 24.1 (5.5) 23.3 (5.7) 24.1 (4.6) — — — —
6 wk 18.9 (10.0) 17.6 (10.6) 15.0 (10.1) 16.3 (10.8) 0.8 (0.0, 1.7) 0.9 (1.8, 3.5) 3.0 (0.3, 5.6) 2.2 (0.6, 4.9)
12 wk 18.1 (9.5) 17.4 (9.2) 15.5 (9.7) 14.7 (10.2) 1.1 (0.2, 1.9)* 0.4 (2.0, 2.8) 1.9 (0.7, 4.5) 3.0 (0.5, 5.6)*
18 wk 17.4 (10.2) 17.6 (10.3) 15.5 (10.3) 14.9 (10.6) 0.8 (0.0, 1.7) 0.6 (3.2, 2.1) 1.2 (1.5, 3.9) 2.2 (0.6, 4.9)
24 wk 16.9 (10.0) 16.5 (10.3) 15.4 (9.5) 13.5 (9.6) 1.0 (0.2, 1.8)* 0.1 (2.5, 2.7) 0.7 (1.8, 3.3) 3.1 (0.5, 5.7)*
39 wk 17.7 (9.8) 15.6 (9.9) 15.1 (10.4) 14.3 (10.6) 0.9 (0.1, 1.7) 1.7 (0.8, 4.2) 1.7 (0.8, 4.3) 3.0 (0.4, 5.6)
52 wk 17.0 (10.2) 15.3 (10.3) 14.0 (10.6) 13.6 (10.4) 1.0 (0.1, 1.8)* 1.3 (1.4, 3.9) 2.1 (0.7, 4.9) 3.0 (0.3, 5.7)
Days with disability (last 4 wk)
0 wk 7.4 (8.1) 6.7 (7.5) 6.8 (7.5) 6.5 (7.2) — — — —
6 wk 2.4 (5.5) 1.6 (3.0) 1.3 (2.7) 1.2 (3.4) 0.3 (0.0, 0.7) 0.8 (0.4, 1.9) 1.0 (0.1, 2.2) 1.1 (0.1, 2.3)
12 wk 3.4 (5.9) 2.6 (4.9) 2.0 (3.3) 2.3 (3.7) 0.4 (0.0, 0.7) 0.6 (0.7, 1.9) 1.3 (0.0, 2.5) 1.0 (0.3, 2.2)
18 wk 2.1 (5.3) 2.2 (5.0) 1.8 (4.1) 2.1 (4.9) 0.1 (0.4, 0.5) 0.1 (1.4, 1.3) 0.3 (0.9, 1.6) 0.0 (1.3, 1.4)
24 wk 3.5 (6.7) 2.7 (5.1) 2.8 (4.6) 2.8 (4.2) 0.1 (0.3, 0.6) 0.7 (0.7, 2.1) 0.6 (0.8, 2.1) 0.5 (0.9, 1.9)
39 wk 2.8 (5.1) 3.0 (5.5) 2.4 (4.7) 2.5 (4.8) 0.1 (0.3, 0.5) 0.3 (1.7, 1.1) 0.4 (0.9, 1.6) 0.2 (1.1, 1.5)
52 wk 3.4 (6.0) 3.4 (6.9) 1.9 (3.7) 2.4 (4.7) 0.4 (0.1, 0.8) 0.1 (1.7, 1.4) 1.5 (0.2, 2.8) 0.8 (0.6, 2.1)
Perceived pain change (six-point Likert)y
6 wk 3.7 (0.9) 4.1 (0.9) 4.3 (1.0) 4.3 (1.0) 0.1 (0.1, 0.2)* 0.2 (0.0, 0.5) 0.4 (0.2, 0.7)* 0.4 (0.1, 0.7)*
12 wk 3.7 (0.9) 3.8 (0.9) 4.0 (1.0) 4.0 (0.9) 0.1 (0.0, 0.2) 0.1 (0.1, 0.4) 0.3 (0.0, 0.5) 0.3 (0.0, 0.5)
18 wk 3.7 (0.9) 4.0 (1.0) 4.1 (1.0) 4.0 (1.0) 0.1 (0.0, 0.2) 0.2 (0.0, 0.5) 0.4 (0.1, 0.7)* 0.2 (0.0, 0.5)
24 wk 3.8 (1.0) 3.9 (1.0) 3.9 (1.0) 3.9 (1.0) 0.0 (0.1, 0.1) 0.1 (0.2, 0.4) 0.1 (0.2, 0.4) 0.1 (0.2, 0.3)
39 wk 3.7 (1.0) 3.8 (1.1) 4.0 (1.0) 4.0 (0.9) 0.1 (0.0, 0.2) 0.1 (0.2, 0.4) 0.3 (0.0, 0.6) 0.3 (0.0, 0.5)
52 wk 3.7 (0.9) 4.0 (1.1) 3.9 (1.1) 4.0 (0.9) 0.1 (0.0, 0.1) 0.3 (0.0, 0.6) 0.2 (0.1, 0.5) 0.2 (0.0, 0.5)
Perceived disability change (six-point Likert)y
6 wk 3.6 (0.9) 3.9 (0.9) 4.0 (1.0) 4.0 (0.9) 0.1 (0.0, 0.2)* 0.3 (0.0, 0.5) 0.4 (0.1, 0.6)* 0.4 (0.2, 0.6)*
12 wk 3.5 (0.9) 3.8 (0.9) 3.8 (1.0) 3.8 (0.9) 0.1 (0.0, 0.2)* 0.2 (0.0, 0.5) 0.3 (0.0, 0.5) 0.3 (0.0, 0.5)
18 wk 3.6 (0.8) 3.7 (1.0) 3.8 (1.0) 3.8 (0.9) 0.1 (0.0, 0.2) 0.1 (0.2, 0.3) 0.2 (0.1, 0.4) 0.2 (0.0, 0.5)
24 wk 3.6 (0.9) 3.7 (0.9) 3.7 (0.9) 3.7 (1.0) 0.0 (0.1, 0.1) 0.1 (0.2, 0.3) 0.1 (0.2, 0.3) 0.1 (0.2, 0.4)
39 wk 3.6 (0.9) 3.7 (1.0) 3.9 (1.0) 3.9 (0.9) 0.1 (0.0, 0.2)* 0.1 (0.2, 0.4) 0.3 (0.1, 0.6)* 0.3 (0.0, 0.5)*
52 wk 3.6 (0.9) 3.8 (1.0) 3.8 (1.1) 3.9 (0.9) 0.1 (0.0, 0.2) 0.2 (0.0, 0.5) 0.2 (0.1, 0.5) 0.3 (0.0, 0.3)
SF-12 physical health component
0 wk 43.0 (9.5) 43.8 (8.9) 44.3 (8.4) 42.3 (8.8) — — — —
12 wk 45.5 (10.3) 47.1 (8.2) 49.6 (8.5) 47.5 (8.5) 1.0 (0.3, 1.6)* 1.2 (0.8, 3.3) 3.5 (1.3, 5.7)* 2.4 (0.3, 4.6)
24 wk 50.0 (11.1) 50.5 (10.1) 51.4 (9.1) 50.9 (9.4) 0.5 (0.3, 1.2) 0.0 (2.3, 2.4) 0.8 (1.6, 3.2) 1.3 (1.1, 3.6)
39 wk 50.6 (11.5) 51.1 (10.3) 52.7 (9.6) 51.8 (9.3) 0.6 (0.2, 1.4) 0.1 (2.3, 2.4) 1.5 (0.9, 4.0) 1.6 (0.9, 4.0)
52 wk 50.7 (12.0) 50.8 (11.0) 52.6 (10.3) 52.5 (8.5) 0.8 (0.1, 1.6) 0.3 (2.7, 2.1) 1.4 (1.2, 4.0) 2.2 (0.2, 4.5)
SF-12 mental health component
0 wk 50.2 (10.5) 48.6 (10.5) 47.6 (11.2) 49.4 (9.6) — — — —
12 wk 50.2 (10.8) 50.4 (9.4) 47.8 (11.0) 48.0 (9.8) 0.7 (1.3,0.0) 1.3 (0.7, 3.3) 0.5 (2.6, 1.5) 1.5 (3.5, 0.4)
24 wk 51.8 (10.9) 52.8 (10.2) 50.8 (11.8) 51.3 (11.2) 0.1 (0.8, 0.6) 2.1 (0.0, 4.2) 0.7 (1.3, 2.8) 0.1 (2.1, 2.2)
39 wk 51.7 (11.3) 51.5 (11.6) 49.2 (13.6) 49.0 (11.7) 0.8 (1.5,0.0) 1.1 (1.3, 3.4) 0.4 (2.9, 2.1) 2.0 (4.3, 0.3)
52 wk 51.3 (12.0) 50.4 (11.4) 50.6 (12.7) 50.4 (11.7) 0.0 (0.8, 0.8) 0.2 (2.3, 2.7) 1.1 (1.6, 3.7) 0.3 (2.9, 2.3)
EuroQol Health State (0–100 scale)
0 wk 70.1 (17.2) 72.1 (13.8) 73.5 (14.4) 68.2 (17.4) — — — —
12 wk 73.5 (17.3) 78.4 (14.1) 77.9 (15.0) 75.7 (14.5) 0.8 (0.4, 2.0) 3.9 (0.0, 7.7) 2.7 (1.3, 6.7) 3.1 (0.8, 6.9)
24 wk 73.9 (17.5) 77.8 (15.5) 77.0 (15.4) 74.5 (16.7) 0.3 (1.0, 1.6) 2.9 (1.0, 6.9) 1.4 (2.6, 5.5) 1.5 (2.7, 5.8)
39 wk 73.1 (20.0) 76.8 (17.2) 76.6 (15.6) 75.3 (16.8) 0.9 (0.5, 2.3) 2.6 (1.9, 7.0) 1.8 (2.6, 6.2) 3.2 (1.3, 7.6)
52 wk 74.8 (17.0) 77.1 (17.0) 77.3 (15.3) 77.2 (14.9) 1.0 (0.3, 2.2) 1.3 (2.7, 5.4) 0.9 (3.1, 4.9) 3.3 (0.5, 7.2)
Nonprescription medication (times in last 4 wk)
0 wk 7.6 (10.0) 8.9 (10.8) 9.5 (10.0) 7.6 (9.4) — — — —
6 wk 4.3 (6.8) 4.1 (6.9) 4.0 (6.7) 4.0 (8.3) 0.1 (0.5, 0.7) 0.6 (1.2, 2.4) 0.9 (0.8, 2.6) 0.3 (1.5, 2.1)
12 wk 7.8 (11.0) 7.1 (23.0) 5.8 (7.6) 7.8 (25.8) 0.1 (1.6, 1.8) 1.4 (2.7, 5.6) 3.2 (0.4, 5.9)* 0.1 (5.5, 5.3)
(Continued)
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Table 4
(Continued )
Time
Observed unadjusted mean (SD) Slope (95% CI) Adjusted mean difference (95% CI)
SMT 0 SMT 6 SMT 12 SMT 18 Per six SMT sessions SMT 0 vs. 6 SMT 0 vs. 12 SMT 0 vs. 18
18 wk 5.7 (7.4) 6.0 (10.4) 5.3 (9.1) 5.5 (9.1) 0.2 (0.5, 0.8) 0.1 (2.4, 2.6) 1.0 (1.1, 3.2) 0.2 (1.8, 2.2)
24 wk 8.1 (13.7) 7.7 (15.8) 6.5 (8.6) 6.4 (10.8) 0.7 (0.4, 1.7) 0.9 (3.3, 5.1) 2.4 (0.7, 5.5) 1.8 (1.5, 5.0)
39 wk 7.2 (14.2) 7.4 (12.2) 6.6 (8.9) 7.7 (13.5) 0.0 (1.1, 1.1) 0.3 (3.4, 4.0) 1.4 (1.9, 4.7) 0.5 (4.0, 3.1)
52 wk 6.5 (8.0) 6.6 (13.7) 6.7 (9.3) 6.8 (12.7) 0.1 (0.9, 0.8) 0.3 (2.7, 3.4) 0.6 (1.5, 2.6) 0.3 (2.9, 2.4)
SMT, spinal manipulative therapy; SD, standard deviation; CI, confidence interval; SF-12, short-form 12.
Unadjusted group means are from original data without imputation; slopes and group differences are computed from imputed data adjusted for the base-
line covariates. Positive signs of slopes and mean differences were computed to favor higher doses of SMT.
* p!.025.
y Likert scale: much worse51, worse52, about the same53, better54, much better55, and completely recovered56.
1114 M. Haas et al. / The Spine Journal 14 (2014) 1106–1116Analyses of the three pain score components gave similar
results and are available from the authors.
Repeated-measures analysis of the full 6- to 52-week
pain profile demonstrated a small advantage of treatment
over control. The largest effect was observed for 12 SMT
visits versus control (AMD55.3, p5.011).
Functional disability
Mean functional disability reduction reached 20 points.
Trends in slopes and group comparisons were similar to
those for pain but smaller in magnitude with fewer statisti-
cally significant results (Table 2). At the 12-week primary
end point, the greatest advantage for SMT over control
was also found for 12 SMT visits (AMD57.5, p5.011),
and at the 24-week primary end point, there were no clini-
cally meaningful effects (AMD !3.4). At 52 weeks, 18
SMT visits were observed to have the greatest effect
(AMD58.8, p5.002). As for pain, there were no clinically
meaningful differences in disability profiles between 12 and
18 SMT visits.
Sensitivity analysis
There were no material changes in the results for pain
and disability outcomes when imputed data were excluded
from the analysis. For the primary end points, changes were
0.3 or less in slope and 1.4 or less/100 points in group dif-
ferences. The changes at other time points were similarly
negligible. Clustering by care provider or clinic produced
no substantive changes in effect sizes.
Responder analysis
The responder profile in Fig. 4 and Table 3 shows that
about 30% to 50% of individuals in each group achieved
50% pain improvement at each time point. Only one statis-
tically significant difference between treatment and control
was found. At 12 weeks, a substantial proportion of re-
sponse to care was attributable to manipulation for 12
SMT visits (21.1%, p5.002). This difference corresponds
to a number needed to treat equal to 5. For functional dis-
ability, about 40% to 60% of individuals were respondersfor all groups and time points. There was only one statisti-
cally significant group difference.
Secondary outcomes
Generally, there was within-group improvement in sec-
ondary outcomes recorded at the end of care showing the
same durability for these outcomes as for pain outcomes.
However, the improvement in the no-SMT control group
was of such magnitude that there were few sizable statisti-
cally significant differences between treatment and control
groups (Table 4).
Days with pain and disability were reduced from base-
line by 1 to 2 per week. Perceived pain and disability
improvement were typically rated as ‘‘better.’’ The stan-
dardized short-form 12 physical health component im-
proved about 7 to 10 points (up to 1 SD), returning to US
population norms in 3 to 6 months. The mental health com-
ponent deviated little from population norms at baseline.
EuroQol Health State Visual Analog Scale showed little
change from baseline. There was a small decrease in med-
ication use after end of care. The mean reductions in pain
unpleasantness scores were similar to pain score reduction,
about 20 points.
Adverse events
There were no notable adverse events. Three persons
reported seeking care for symptomatic relief of LBP exac-
erbation related to the study. One ineligible person subse-
quently reported increase of pain after the screening
examination. One participant in the 12-SMT group lost sev-
eral days of work followed by complete resolution or the
episode during the treatment phase. One participant in the
12-SMT group dropped out after an exacerbation associ-
ated with lifting a child.Discussion
This first full-scale dose-response study of SMT had sev-
eral notable findings. Based on the pain and functional
disability primary outcomes, 12 sessions of SMT yielded
the overall best, albeit modest, treatment effects (group
1115M. Haas et al. / The Spine Journal 14 (2014) 1106–1116differences). This was particularly noted in the short term at
the 12-week primary end point. Group differences were neg-
ligible at the 24-week primary end point and favored 18
SMT sessions to a small degree in the long term, at 52 weeks.
In general, the data were consistent with a dose-response re-
lationship being saturated at 12 sessions with little or no ad-
ditional benefit attributable to additional SMT visits, even at
52 weeks. Analysis of the full-time profile supported no ad-
ditional benefit overall of 18 over 12 sessions. In addition,
responder analysis gave additional support for some advan-
tage of 12 visits but only in the short term.
The linear dose-response gradients for the primary out-
comes were small in general, reaching approximately
2/100 scale points per six sessions of SMT at 12 and 52
weeks. Even excluding the highest dose group for short-
term results, the gradient would only double to about
4/100 scale points per six SMT sessions. The fact that there
was little difference between adjacent dose groups makes it
difficult to recommend one treatment dose over another.
However, two considerations come into play. First, the ef-
fects across dose accumulate to modest benefit of SMT
above the hands-on control. Second, an aim of the study
was to find a saturation dose level for use in future studies.
The time profiles, dose-response gradients, and compari-
sons with the control group suggest in aggregate that 12
visits would be the best choice, particularly for short-term
improvement.
Interpretation of the dose-response effects requires con-
sideration of several factors. This was a fastidious random-
ized trial designed to isolate the effects of SMT. We
controlled number of visits, time with the participant, ef-
fects of touching the patient, patient-provider interaction,
and intervention credibility. This was accomplished with
18 visits of hands-on therapy and electronic modality (min-
imal ultrasound) for all groups. The specific and contextual
effects of light massage at non-SMT visits, ultrasound, or
simply 18 visits to a health-care provider potentially obfus-
cated a larger dose-response gradient that might be found in
clinical practice. For example, such larger effects were seen
in our pilot study where participants attended only visits for
the active intervention [5].
In terms of efficacy, the light massage control is techni-
cally a comparison intervention rather than a true sham.
Many sessions with even a minimal massage may have
more effect than one might expect. As such, the differences
between SMT and the control may be somewhat smaller
than for a comparison with a sham manipulation. We did
not attempt to use a sham for two reasons. First, it would
be virtually impossible to blind participants because half re-
ceived visits for both treatment and control and could com-
pare interventions. Second, we wanted to avoid some
disappointment that can arise when participants think they
may be receiving sham intervention.
All participants were scheduled to receive their assigned
dose of SMT. There were no treatment stoppage rules based
on improvement during the care period. The effects of carestoppage are unknown and could be either beneficial or det-
rimental to outcomes in the short and long terms.
Another issue is the threshold of a clinically important
difference between groups for the continuous variable pri-
mary outcomes. Studies on patient-rated minimal important
change have led some authors to conclude that 30%
improvement (about 15–20/100 points) can be considered
a robust indicator of within-person minimal clinically im-
portant change for these outcomes [35]. A 50% improve-
ment has been recommended as a success threshold for the
individual [36]. However, Dworkin et al. [37] point out that
these numbers do not apply to between-group effects, and
identifying meaningful group differences is a multifactorial
process that is far from straightforward. The between-group
differences of 8.6 in pain and 7.5 in disability scores at a
primary end point are certainly marginal, but it is not clear
yet whether effects of this magnitude constitute a degree
of clinical relevance. The associated number needed to treat
for pain (55) may actually indicate a meaningful effect
[12,38].
Conclusions
Overall, 12 sessions of spinal manipulation in 6 weeks
from a chiropractor yielded the most favorable pain and
functional disability improvement for chronic nonspecific
LBP. Mean participant improvement for this group was sub-
stantial at the end of care and sustainable to 52 weeks. Ap-
proximately, half of patients would be expected to achieve
50% improvement in pain/disability. Therefore, 12 sessions
of SMT is the current best estimate for use in comparative
effectiveness trials. However, the recommendation is made
with caution because the gradient of treatment effects across
dose groups was too small to clearly distinguish 12 visits
from adjacent dose levels. Even with 12 visits, the contribu-
tion of SMT to outcomes beyond that of a focused light mas-
sage delivered by a chiropractor (hands-on control) was at
best modest at the 12-week primary end point and negligible
at the 24-week primary end point.Acknowledgments
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